Scalbert E, Richer C, Giudicelli J F
Département de Pharmacologie, Faculté de Médecine Paris-Sud, Le Kremlin-Bicetre, France.
J Cardiovasc Pharmacol. 1989 Jan;13(1):94-104.
The interactions between ketanserin and serotonin (5-HT)- and alpha-adrenoceptor agonists (alpha 1, cirazoline; alpha 2, UK-14,304)-induced systemic and regional (kidney, hindquarter, mesentery) hemodynamic responses were investigated in the pithed spontaneously hypertensive rat (SHR) using the pulsed Doppler technique. Serotonin, cirazoline, and UK-14,304 dose dependently increased systemic blood pressure and local vascular resistances. However, the regional vasoconstrictor profiles of serotonin (hindquarter greater than kidney greater than mesentery) and cirazoline (kidney greater than hindquarter greater than mesentery) were found not to be homogeneous. Ketanserin antagonized the systemic and regional hemodynamic effects of serotonin and cirazoline but not of UK-14,304. The ketanserin-serotonin antagonism was noncompetitive and occurred at doses (3-30 micrograms/kg) 100-fold lower than those (300-3,000 micrograms/kg) at which a presumably competitive antagonism developed between ketanserin and cirazoline. Furthermore, ketanserin antagonized serotonin, as well as cirazoline, homogeneously in all vascular beds. These data together with those previously obtained with ketanserin in the intact SHR (reduction in blood pressure starting at 300 micrograms/kg, heterogeneous regional vasodilator profile: hindquarter greater than kidney greater than mesentery) indicate that (a) the antihypertensive effects of ketanserin in the SHR can principally, although perhaps not exclusively, be ascribed to the drug's alpha 1-adrenoceptor blocking properties, and (b) the heterogeneous regional vasodilator profile of the drug is not due solely to the homogeneous antagonism that it exhibits versus the regional vasoconstrictor effects of alpha 1-adrenoceptors activation.
采用脉冲多普勒技术,在脊髓横断的自发性高血压大鼠(SHR)中研究了酮色林与5-羟色胺(5-HT)及α-肾上腺素能受体激动剂(α1,西拉唑啉;α2,UK-14,304)诱导的全身和局部(肾脏、后肢、肠系膜)血流动力学反应之间的相互作用。5-羟色胺、西拉唑啉和UK-14,304剂量依赖性地升高全身血压和局部血管阻力。然而,发现5-羟色胺(后肢>肾脏>肠系膜)和西拉唑啉(肾脏>后肢>肠系膜)的局部血管收缩特征并不一致。酮色林拮抗5-羟色胺和西拉唑啉的全身和局部血流动力学效应,但不拮抗UK-14,304的效应。酮色林-5-羟色胺拮抗作用是非竞争性的,且发生时的剂量(3-30微克/千克)比酮色林与西拉唑啉之间可能出现竞争性拮抗作用时的剂量(300-3000微克/千克)低100倍。此外,酮色林在所有血管床中均能均匀地拮抗5-羟色胺以及西拉唑啉。这些数据与先前在完整SHR中使用酮色林所获得的数据(从300微克/千克开始血压降低,局部血管舒张特征不均一:后肢>肾脏>肠系膜)一起表明:(a)酮色林在SHR中的降压作用虽然可能并非完全,但主要可归因于该药物的α1-肾上腺素能受体阻断特性;(b)该药物局部血管舒张特征的不均一性并非仅仅由于它对α1-肾上腺素能受体激活所致的局部血管收缩效应表现出的均匀拮抗作用。